Molly Catherine Hardebeck

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Stephen Johnston, Miguel Martín, Angelo Di Leo et al. · npj Breast Cancer · 2019 · 676 citations · Full text

Medicine, Oncology, Pharmacology +16

Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice

Nozomi Tomimatsu, Bipasha Mukherjee, Molly Catherine Hardebeck et al. · Nature Communications · 2014 · 180 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Carlos R. Gil Del Alcazar, Molly Catherine Hardebeck, Bipasha Mukherjee et al. · Clinical Cancer Research · 2013 · 170 citations · Full text

Medicine, Cancer Biology, Oncology +17

DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair

Nozomi Tomimatsu, Bipasha Mukherjee, Janelle L. Harris et al. · Journal of Biological Chemistry · 2017 · 80 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

Angelo Di Leo, Joyce O’Shaughnessy, George W. Sledge et al. · npj Breast Cancer · 2018 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17